Zobrazeno 1 - 10
of 127
pro vyhledávání: '"Martin A. Cheever"'
Autor:
Darci Phillips, Magdalena Matusiak, Belén Rivero Gutierrez, Salil S. Bhate, Graham L. Barlow, Sizun Jiang, Janos Demeter, Kimberly S. Smythe, Robert H. Pierce, Steven P. Fling, Nirasha Ramchurren, Martin A. Cheever, Yury Goltsev, Robert B. West, Michael S. Khodadoust, Youn H. Kim, Christian M. Schürch, Garry P. Nolan
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-18 (2021)
PD-1 blockade is effective for only a subset of patients with cutaneous T cell lymphomas. Here, the authors report a spatial biomarker that uses immune and cancer cell topography to predict response to PD-1 blockade in this disease.
Externí odkaz:
https://doaj.org/article/185b95b3ae0241efb2f75ef0ed8fba8c
Autor:
Natalie J. Miller, Candice D. Church, Steven P. Fling, Rima Kulikauskas, Nirasha Ramchurren, Michi M. Shinohara, Harriet M. Kluger, Shailender Bhatia, Lisa Lundgren, Martin A. Cheever, Suzanne L. Topalian, Paul Nghiem
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-9 (2018)
Abstract Background Merkel cell carcinoma (MCC) is an aggressive skin cancer that frequently responds to anti-PD-1 therapy. MCC is associated with sun exposure and, in 80% of cases, Merkel cell polyomavirus (MCPyV). MCPyV-specific T and B cell respon
Externí odkaz:
https://doaj.org/article/e8021ab7a1ff40af8dd91b15754b2650
Autor:
Marc S. Ernstoff, Hing C. Wong, Martin A. Cheever, Amy D. Rock, Peter R. Rhode, Monica Jones, Jack O. Egan, Judith C. Kaiser, Steven P. Fling, Andreanne M. Lacroix, Shernan G. Holtan, Ann W. Silk, Sylvia M. Lee, Jeffrey S. Miller, Vamsidhar Velcheti, Chihiro Morishima, Kim Margolin
Supplementary Figure 1-3 Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5afa04c5632d390b11e61ebbd0008456
https://doi.org/10.1158/1078-0432.22469901
https://doi.org/10.1158/1078-0432.22469901
Autor:
Lynn M. Matrisian, Louis M. Weiner, Jaye L. Viner, Sheila A. Prindiville, Ira Mellman, Toby T. Hecht, Benjamin M. Hastings, Olivera J. Finn, Andrea S. Ferris, James P. Allison, Martin A. Cheever
Supplementary Data from The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06d3615ccbc0662f0a15b50a6b909c00
https://doi.org/10.1158/1078-0432.22440673.v1
https://doi.org/10.1158/1078-0432.22440673.v1
Autor:
Lynn M. Matrisian, Louis M. Weiner, Jaye L. Viner, Sheila A. Prindiville, Ira Mellman, Toby T. Hecht, Benjamin M. Hastings, Olivera J. Finn, Andrea S. Ferris, James P. Allison, Martin A. Cheever
The purpose of the National Cancer Institute pilot project to prioritize cancer antigens was to develop a well-vetted, priority-ranked list of cancer vaccine target antigens based on predefined and preweighted objective criteria. An additional aim wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b6dee98aa94e2fdf60413125e8a48cf
https://doi.org/10.1158/1078-0432.c.6517972
https://doi.org/10.1158/1078-0432.c.6517972
Autor:
Marc S. Ernstoff, Hing C. Wong, Martin A. Cheever, Amy D. Rock, Peter R. Rhode, Monica Jones, Jack O. Egan, Judith C. Kaiser, Steven P. Fling, Andreanne M. Lacroix, Shernan G. Holtan, Ann W. Silk, Sylvia M. Lee, Jeffrey S. Miller, Vamsidhar Velcheti, Chihiro Morishima, Kim Margolin
Purpose: IL15 induces the activation and proliferation of natural killer (NK) and memory CD8+ T cells and has preclinical antitumor activity. Given the superior activity and favorable kinetics of ALT-803 (IL15N72D:IL15RαSu/IgG1 Fc complex) over reco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::386676f2f3598b4c8df5385ba0517278
https://doi.org/10.1158/1078-0432.c.6527382.v1
https://doi.org/10.1158/1078-0432.c.6527382.v1
Autor:
Marc S. Ernstoff, Hing C. Wong, Martin A. Cheever, Amy D. Rock, Peter R. Rhode, Monica Jones, Jack O. Egan, Judith C. Kaiser, Steven P. Fling, Andreanne M. Lacroix, Shernan G. Holtan, Ann W. Silk, Sylvia M. Lee, Jeffrey S. Miller, Vamsidhar Velcheti, Chihiro Morishima, Kim Margolin
Supplemental Figure 1. Effect of ALT-803 treatment on white blood cell and lymphocyte counts in i.v. dose cohorts Supplemental Figure 2. Circulating NK cell expansion during ALT-803 treatment Supplemental Figure 3. Effect of subcutaneous ALT-803 on c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeb7495845ae7a2a25b3ea58d3810e26
https://doi.org/10.1158/1078-0432.22469895.v1
https://doi.org/10.1158/1078-0432.22469895.v1
Autor:
Kunle Odunsi, Feng Qian, Amit A. Lugade, Han Yu, Melissa A. Geller, Steven P. Fling, Judith C. Kaiser, Andreanne M. Lacroix, Leonard D’Amico, Nirasha Ramchurren, Chihiro Morishima, Mary L. Disis, Lucas Dennis, Patrick Danaher, Sarah Warren, Van Anh Nguyen, Sudharshan Ravi, Takemasa Tsuji, Spencer Rosario, Wenjuan Zha, Alan Hutson, Song Liu, Shashikant Lele, Emese Zsiros, A. J. Robert McGray, Jessie Chiello, Richard Koya, Thinle Chodon, Carl D. Morrison, Vasanta Putluri, Nagireddy Putluri, Donald E. Mager, Rudiyanto Gunawan, Martin A. Cheever, Sebastiano Battaglia, Junko Matsuzaki
Publikováno v:
Sci Transl Med
To uncover underlying mechanisms associated with failure of indoleamine 2,3-dioxygenase 1 (IDO1) blockade in clinical trials, we conducted a pilot, window-of-opportunity clinical study in 17 patients with newly diagnosed advanced high-grade serous ov
Autor:
Davide Bedognetti, Patrick Danaher, Mary L. Disis, Brent A. Hanks, Chihiro Morishima, Nina Bhardwaj, Anna C. Pavlick, Andres M. Salazar, Jason J. Luke, Ena Wang, Sarah Warren, Philip Friedlander, Lisa Lundgren, Steven P. Fling, Marc S. Ernstoff, Ana Belen Blazquez, Tibor Keler, Brendan D. Curti, Martin A. Cheever, Sreekumar Balan, Leonard A D'Amico, Michael J. Yellin, Thomas A. Davis, Bruce W. Hess, Bob Salim, Laura Vitale, Joseph M. Beechem, Elad Sharon, Darawan Rinchai, Nirasha Ramchurren, Brian R. Gastman, Andrea Crocker, Thomas Hawthorne, Mark R. Albertini
Publikováno v:
Nature Cancer. 1:1204-1217
Generating responses to tumor antigens poses a challenge for immunotherapy. This phase II trial (NCT02129075) tested fms-like tyrosine kinase 3 (Flt3) ligand pre-treatment enhancement of responses to dendritic cell (DC)-targeting vaccines. We evaluat
Autor:
Thomas S. Uldrick, Scott V. Adams, Remi Fromentin, Michael Roche, Steven P. Fling, Priscila H. Gonçalves, Kathryn Lurain, Ramya Ramaswami, Chia-ching Jackie Wang, Robert J. Gorelick, Jorden L. Welker, Liz O’Donoghue, Harleen Choudhary, Jeffrey D. Lifson, Thomas A. Rasmussen, Ajantha Rhodes, Carolin Tumpach, Robert Yarchoan, Frank Maldarelli, Martin A. Cheever, Rafick Sékaly, Nicolas Chomont, Steven G. Deeks, Sharon R. Lewin
Publikováno v:
Sci Transl Med
Science translational medicine, vol 14, iss 629
Uldrick, T S, Adams, S V, Fromentin, R, Roche, M, Fling, S P, Gonçalves, P H, Lurain, K, Ramaswami, R, Jackie Wang, C C, Gorelick, R J, Welker, J L, O'Donoghue, L, Choudhary, H, Lifson, J D, Rasmussen, T A, Rhodes, A, Tumpach, C, Yarchoan, R, Maldarelli, F, Cheever, M A, Sékaly, R, Chomont, N, Deeks, S G & Lewin, S R 2022, ' Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy ', Science Translational Medicine, vol. 14, no. 629, eabl3836 . https://doi.org/10.1126/scitranslmed.abl3836
Science translational medicine, vol 14, iss 629
Uldrick, T S, Adams, S V, Fromentin, R, Roche, M, Fling, S P, Gonçalves, P H, Lurain, K, Ramaswami, R, Jackie Wang, C C, Gorelick, R J, Welker, J L, O'Donoghue, L, Choudhary, H, Lifson, J D, Rasmussen, T A, Rhodes, A, Tumpach, C, Yarchoan, R, Maldarelli, F, Cheever, M A, Sékaly, R, Chomont, N, Deeks, S G & Lewin, S R 2022, ' Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy ', Science Translational Medicine, vol. 14, no. 629, eabl3836 . https://doi.org/10.1126/scitranslmed.abl3836
In people living with HIV (PLWH) on antiretroviral therapy (ART), virus persists in a latent form where there is minimal transcription or protein expression. Latently infected cells are a major barrier to curing HIV. Increasing HIV transcription and